For Young Men With Secondary Hypogonadism, Enclomiphene Deserves the First Prescription, Not Testosterone

By
Published Updated Last reviewed
Hormone therapy clinical care image for For Young Men With Secondary Hypogonadism, Enclomiphene Deserves the First Prescription, Not Testosterone

The clinical habit this editorial is pushing back against

A man in his late twenties walks into a primary care visit with fatigue, reduced libido, and a total testosterone of 280 ng/dL. His LH is low-normal. His FSH is low-normal. He has no children yet and is not sure he wants them. The clinician orders a repeat testosterone, confirms the number, and starts him on testosterone cypionate 100 mg IM weekly.

That sequence happens thousands of times a week across the United States. It is not obviously wrong. Testosterone cypionate is FDA-approved, inexpensive, and reliably effective at raising serum testosterone. But in a man with secondary hypogonadism, meaning the testes are capable but the hypothalamic-pituitary signal is insufficient, it forecloses a real alternative that preserves HPG-axis function, maintains spermatogenesis, and may be equally effective at symptom resolution. That alternative is enclomiphene citrate.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy explicitly states that testosterone therapy should not be offered to men who are "currently trying to father a child," and recommends referral to a reproductive endocrinologist in those cases. What the guideline does not do is create a clear decision pathway for the large middle category: the young man who is not trying to conceive right now but has not completed family planning and has secondary hypogonadism that could theoretically respond to HPG-axis stimulation.

That gap is where enclomiphene belongs. And it is where the reflexive testosterone prescription does lasting, sometimes irreversible, harm.

The evidence base

Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene as a racemic mixture has been used off-label in men for decades, but the zuclomiphene (cis) isomer accumulates in tissue and carries estrogenic activity that may blunt the desired effect. Enclomiphene isolates the estrogen receptor antagonist activity at the hypothalamus, which disinhibits GnRH pulsatility and increases LH and FSH secretion.

The key trial data come from Kim et al., published in BJU International in 2016. In that randomized, double-blind study of men with secondary hypogonadism, enclomiphene 12.5 mg and 25 mg daily raised mean morning testosterone from hypogonadal baseline levels to the normal range, with the 25 mg dose achieving mean testosterone concentrations of approximately 500 ng/dL at 16 weeks. Critically, LH and FSH also rose. In the testosterone gel comparator arm, serum testosterone normalized but LH and FSH fell, as expected from exogenous androgen suppression of the pituitary. Sperm concentration was maintained in the enclomiphene arms and fell in the testosterone arm. The study was not powered to assess symptom outcomes as a primary endpoint, which is a limitation we address below.

Earl et al., writing in Sexual Medicine Reviews in 2019, synthesized the available enclomiphene trial data and concluded that the agent "restores normal testosterone levels and maintains spermatogenesis in men with secondary hypogonadism, offering a potential alternative to traditional testosterone replacement therapy." They noted that across the Androxal (enclomiphene's investigational name) clinical development program, multiple Phase II and Phase III trials confirmed the biochemical effect, with no new safety signals beyond mild GI side effects and transient visual symptoms in a minority of patients.

The Endocrine Society 2018 guideline also observes that in men with secondary hypogonadism caused by functional conditions (obesity, opioid use, hyperprolactinemia, hypothyroidism), treatment of the underlying cause may itself restore testosterone levels. Enclomiphene occupies a complementary space: it is appropriate when the underlying cause is partially corrected or when a functional HPG deficit persists.

What the data show is consistent across the trial program. In the Phase III trial included in the Androxal NDA package, approximately 75% of enclomiphene-treated subjects achieved testosterone >300 ng/dL by week 16, compared with roughly 90% in the topical testosterone arm, a modest efficacy gap that the FDA ultimately used, alongside the absence of an approved manufacturing pathway, to justify declining approval of Androxal in 2013. That decision did not reflect a safety finding. It reflected a regulatory determination that the clinical benefit over existing therapies was not sufficiently differentiated for the general hypogonadism indication. The agency's complete response letter cited the need for better symptom-endpoint data, not a toxicity signal.

This matters because it means enclomiphene is not FDA-approved, but the reason it is not approved is a regulatory and commercial calculation, not a finding of harm. Prescribers conflate these two facts routinely.

Where the consensus falls short

The standard clinical reflex of prescribing testosterone for any confirmed low T in a symptomatic man is defensible in older men with primary hypogonadism who have completed family planning. It is a poor default in men under 40 with secondary hypogonadism for three reasons.

First, testosterone cypionate reliably suppresses spermatogenesis. The WHO Task Force on Methods for the Regulation of Male Fertility demonstrated decades ago that weekly testosterone enanthate at 200 mg suppressed sperm concentration to azoospermia or severe oligozoospermia in the majority of participants. Suppression may be reversible with discontinuation, but recovery is neither guaranteed nor rapid. A 2006 meta-analysis by Liu et al. in the Journal of Clinical Endocrinology and Metabolism found median time to recovery of sperm concentration to pretreatment levels was approximately 3.4 months after stopping short courses, but recovery was less predictable after longer exposures and in men with baseline subfertility. For a 28-year-old who "isn't sure" about children, starting a potentially indefinite course of exogenous testosterone is a decision with a fertility consequence that deserves to be made explicitly, not by default.

Second, secondary hypogonadism is not always permanent. Causes including obesity, sleep apnea, opioid use, and hyperprolactinemia are addressable. The Endocrine Society guideline specifically recommends evaluating for reversible causes before initiating testosterone. When a reversible cause is corrected, the HPG axis may recover. Starting exogenous testosterone before completing that evaluation introduces exogenous suppression that can complicate the clinical picture and delay recognition of recovery.

Third, the framing of enclomiphene as "unproven" because it lacks FDA approval overstates the evidentiary gap. The Kim et al. BJU International 2016 trial was a randomized controlled trial with an active comparator. The Earl et al. Sex Med Rev 2019 review synthesized multiple trials from the Androxal program. The biochemical efficacy is established. The gap is symptom-endpoint data from adequately powered trials. That is a real limitation. But the same gap exists in much of the testosterone literature. The TRAVERSE trial is the largest cardiovascular safety trial of testosterone, not a symptom-efficacy trial, and even it enrolled men aged 45-80 with cardiovascular risk factors, not the young secondary hypogonadism population we are describing here.

The compounding problem we are not allowed to ignore

Here is where we extend beyond guideline language, based on clinical judgment and pharmacovigilance concern rather than RCT evidence.

Enclomiphene is not commercially available in the United States as an approved single-agent product. Racemic clomiphene (Clomid, generics) is FDA-approved but for female infertility. Enclomiphene as a standalone compound for men must be obtained from a compounding pharmacy operating under 503A or 503B regulatory frameworks. This is legal. It is also a source of real quality-control risk that most primary care prescribers do not think carefully about.

The FDA's 2023 guidance on compounding and the DQSA created a framework for 503B outsourcing facilities with tighter manufacturing standards, but 503A pharmacies, which fill individual prescriptions, operate under state pharmacy board oversight that varies substantially. Potency, sterility (for injectable compounds), and dosage uniformity are not verified by FDA inspection for 503A facilities. A 2021 analysis published in JAMA found meaningful variability in active pharmaceutical ingredient concentration across compounded hormone products. Enclomiphene is an oral compound, which reduces sterility risk compared to injectable testosterone, but dosage uniformity and degradation remain real concerns.

Our practical concern is this: a primary care physician prescribes enclomiphene 25 mg daily from a compounding pharmacy. The patient receives a product with 18 mg or 31 mg of active compound. At 18 mg, the patient may not reach therapeutic testosterone levels and the prescriber concludes enclomiphene "doesn't work." At 31 mg, the patient gets estrogenic side effects from a supraphysiologic dose. Neither outcome reflects the agent's actual performance in the clinical trials.

This is not a reason to avoid enclomiphene. It is a reason to prescribe it thoughtfully, to use PCAB-accredited or FDA-registered 503B outsourcing pharmacies where possible, and to monitor labs at 4 to 8 weeks with the understanding that dose adjustment may be needed based on a product whose stated dose should be treated as approximate.

Our position

The HealthRX Medical Team holds the following position, with the reasoning chain made visible:

Men under 40 with biochemically confirmed secondary hypogonadism (low or low-normal LH, low testosterone, intact pituitary anatomy) who have not completed family planning or who have not had a reversible cause excluded should be offered a trial of enclomiphene before starting testosterone replacement. The rationale rests on three sequential claims: first, exogenous testosterone suppresses spermatogenesis and HPG-axis function in a population where that axis may be rescuable; second, enclomiphene has demonstrated capacity to raise testosterone, LH, and FSH simultaneously in RCT data, even if symptom-endpoint trials are underpowered; and third, the fertility and HPG-axis consequences of early testosterone are not trivial and deserve to be weighed explicitly.

We acknowledge this position goes beyond what any current guideline explicitly recommends as a default sequence. The Endocrine Society 2018 guideline advises against testosterone in men who are actively trying to conceive, but it does not establish enclomiphene as a preferred first step in the broader secondary hypogonadism population. We are extending that logic on clinical grounds, not on the basis of a head-to-head symptom-outcome trial.

We also hold that prescribing enclomiphene from a compounding pharmacy without discussing the quality-control limitations with the patient is incomplete informed consent. The patient should know the drug is not FDA-approved as a standalone product, that the compounded preparation carries dosage uncertainty, and that labs at 4 to 8 weeks are non-negotiable to verify response. The compounding pathway is workable. It is not transparent by default.

What would change our mind

A well-powered randomized trial comparing enclomiphene to testosterone cypionate in men under 40 with secondary hypogonadism, using validated symptom endpoints (ADAM questionnaire, IIEF, fatigue scales) as the primary outcome, with 12-month follow-up and semen analysis as a co-primary, would be the study that settles this. If enclomiphene showed no meaningful symptom benefit over placebo at adequate testosterone levels, or if its biochemical effect was inconsistent at the doses achievable through compounded product, we would revise the recommendation toward earlier testosterone. FDA approval of a commercially manufactured enclomiphene product would also remove the compounding burden and make the risk-benefit calculation substantially cleaner.

Short of that, prescribers comfortable with off-label use in a population where the stakes of premature HPG suppression are high should default to trying enclomiphene first. The testosterone prescription can always come later. The HPG axis, once suppressed for years, may not come back.

Frequently asked questions

References

  • Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. https://pubmed.ncbi.nlm.nih.gov/26614366/
  • Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
  • Earl JA, Kim ED. Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019;14(3):157-165. https://pubmed.ncbi.nlm.nih.gov/30538055/
  • WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65(4):821-829. https://pubmed.ncbi.nlm.nih.gov/8678082/
  • Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412-1420. https://pubmed.ncbi.nlm.nih.gov/16622143/
  • Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37316241/
  • Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29601923/
  • Pines A. Compounding pharmacies and hormone therapy. Climacteric. 2021;24(4):330-333. https://pubmed.ncbi.nlm.nih.gov/33822997/
  • FDA. Compounding Laws and Policies. U.S. Food and Drug Administration. 2023. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
  • Sigman M. The evaluation and treatment of male infertility. In: Wein AJ, ed. Campbell-Walsh Urology. 11th ed. Referenced in practice context. See also: Male Infertility Best Practice Policy Committee, American Urological Association. https://www.auanet.org/guidelines-and-quality/guidelines/male-infertility